OC
MCID: OVR078
MIFTS: 50

Ovarian Cancer, Somatic (OC) malady

Categories: Genetic diseases (common), Cancer diseases

Aliases & Classifications for Ovarian Cancer, Somatic

About this section

Aliases & Descriptions for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 52 24 12
Adenocarcinoma, Ovarian, Somatic 52 12
Epithelial Ovarian Cancer 70 68
Malignant Neoplasm of Ovary 68
 
Ovarian Carcinoma, Somatic 52
Ovarian Carcinoma 68
Ovarian Cancer 70
Oc 70

Characteristics:

HPO:

64
ovarian cancer, somatic:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 167000
MeSH39 D010051

Summaries for Ovarian Cancer, Somatic

About this section
OMIM:52 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with... (167000) more...

MalaCards based summary: Ovarian Cancer, Somatic, also known as adenocarcinoma, ovarian, somatic, is related to glossopharyngeal motor neuropathy and diphallia, and has symptoms including pelvic pain, abnormality of metabolism/homeostasis and breast carcinoma. An important gene associated with Ovarian Cancer, Somatic is OPCML (Opioid Binding Protein/Cell Adhesion Molecule Like), and among its related pathways are Nongenotropic Androgen signaling and RHO GTPases activate IQGAPs. Affiliated tissues include ovary and breast, and related mouse phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin.

UniProtKB/Swiss-Prot:70 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Related Diseases for Ovarian Cancer, Somatic

About this section

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 87)
idRelated DiseaseScoreTop Affiliating Genes
1glossopharyngeal motor neuropathy10.2CDH1, ERBB2
2diphallia10.2CDH1, ERBB2
3reactive arthritis10.2CTNNB1, ERBB2, PIK3CA
4adult syndrome10.2CTNNB1, KRAS, PIK3CA
5progesterone-receptor negative breast cancer10.2AKT1, ERBB2, PIK3CA
6substance abuse10.2CDH1, CTNNB1, ERBB2
7keratosis linearis with ichthyosis congenita and sclerosing keratoderma10.2BRCA2, PIK3CA
8spongiotic dermatitis10.2ERBB2, KRAS, PIK3CA
9vascular hemostatic disease10.1ERBB2, KRAS, PIK3CA
10spastic diplegia infantile type10.1CTNNB1, ERBB2, KRAS
11breast ductal carcinoma10.1CTNNB1, KRAS
12ideomotor apraxia10.1CDH1, CTNNB1, KRAS
13advanced sleep phase syndrome10.1CDH1, CTNNB1, KRAS
14prostatic adenoma10.1CTNNB1, ERBB2, KRAS
15melanocytic nevus syndrome, congenital, somatic10.1KRAS, PIK3CA
16oral squamous cell carcinoma10.1CDH1, CTNNB1, KRAS
17gastroesophageal junction adenocarcinoma10.1CDH1, CTNNB1, KRAS
18casp10-related autoimmune lymphoproliferative syndrome10.1BRCA2, PIK3CA
19uterine corpus endometrial stromal sarcoma10.1BRCA1, KRAS, PIK3CA
20pulmonary fibrosis and/or bone marrow failure, telomere-related, 110.1CDH1, ERBB2, KRAS
21histiocytic and dendritic cell cancer10.1BRCA1, ERBB2
22urethral cancer10.1KRAS, PIK3CA
23aorto-ventricular tunnel10.1BRCA1, BRCA2
24benign shuddering attacks10.1AKT1, CDH1, KRAS
25osteopetrosis10.1
26solitary plasmacytoma of chest wall10.1CDH1, CTNNB1, ERBB2
27in situ pulmonary adenocarcinoma10.1AKT1, CDH1, CTNNB1
28monoclonal paraproteinemia10.1CDH1, CTNNB1, KRAS
29burn scar10.0BRCA1, BRCA2
30lethal congenital contracture syndrome 710.0BRCA1, BRCA2
31gastric cancer, somatic10.0CDH1, ERBB2, KRAS, PIK3CA
32autoimmune disease of cardiovascular system10.0BRCA1, BRCA2
33heart malignant hemangiopericytoma10.0BRCA1, BRCA2
34facial dermatosis10.0CDH1, CTNNB1, ERBB2, KRAS
35peritoneal mesothelioma10.0CDH1, CTNNB1, KRAS, PIK3CA
36ladd syndrome10.0CDH1, ERBB2, KRAS, PIK3CA
37congenital bile acid synthesis defect10.0BRCA2, ERBB2, PALB2
38macrocytic anemia10.0CTNNB1, KRAS
39glycogen storage disease10.0CDH1, CTNNB1, ERBB2, KRAS
40mediastinum synovial sarcoma10.0BRCA1, BRCA2, PIK3CA
41kunjin encephalitis10.0BRCA1, BRCA2, ERBB2
42lung clear cell-sugar-tumor10.0BRCA1, BRCA2, ERBB2
43breast malignant phyllodes tumor10.0BRCA1, CDH1, CTNNB1, ERBB2
44bladder colloid adenocarcinoma10.0BRCA1, BRCA2, ERBB2
45polyembryoma of the ovary10.0BRCA1, BRCA2, ERBB2
46fallopian tube carcinosarcoma10.0BRCA1, BRCA2, ERBB2
47immunodeficiency due to a late component of complement deficiency10.0BRCA1, BRCA2, ERBB2
48metagonimiasis9.9BRCA1, BRCA2, ERBB2
49pituitary stalk meningioma9.9BRCA1, BRCA2, ERBB2
50bacteremia9.9BRCA1, BRCA2, PALB2

Comorbidity relations with Ovarian Cancer, Somatic via Phenotypic Disease Network (PDN):


Deficiency AnemiaNeutropenia
HydronephrosisProtein-Energy Malnutrition
Acute CystitisUterine Fibroid
Peritoneum CancerFallopian Tube Carcinoma
Intestinal ObstructionParalytic Ileus

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to ovarian cancer, somatic

Symptoms & Phenotypes for Ovarian Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

167000

Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer, Somatic:

 64
id Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis64 HP:0001939
2 breast carcinoma64 HP:0003002
3 ovarian papillary adenocarcinoma64 HP:0006774
4 dysgerminoma64 HP:0100621

UMLS symptoms related to Ovarian Cancer, Somatic:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00101-A-49.2BRCA1, BRCA2, BRIP1
2GR00101-A-19.1BRCA1, BRCA2, BRIP1
3GR00250-A-17.8AKT1, BRCA1, BRCA2, BRIP1, PALB2, PRKN

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

41 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.6CDH1, CTNNB1, KRAS, OPCML, PIK3CA, PRKN
2MP:00053888.1AKT1, BRCA1, CTNNB1, ERBB2, KRAS, PRKN
3MP:00053697.9AKT1, BRCA1, CTNNB1, ERBB2, KRAS, PIK3CA
4MP:00053717.9BRCA1, BRCA2, CTNNB1, ERBB2, KRAS, PALB2
5MP:00053817.8BRCA1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
6MP:00028737.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
7MP:00053907.5AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
8MP:00053807.1AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
9MP:00053896.9AKT1, BRCA1, BRCA2, BRIP1, CDH1, CTNNB1
10MP:00107686.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
11MP:00053856.5AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS
12MP:00053766.5AKT1, BRCA1, BRCA2, BRIP1, CDH1, CTNNB1
13MP:00053796.5AKT1, BRCA1, BRCA2, BRIP1, CDH1, CTNNB1
14MP:00107716.3AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
15MP:00053786.1AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
16MP:00020066.0AKT1, BRCA1, BRCA2, BRIP1, CDH1, CTNNB1
17MP:00053846.0AKT1, BRCA1, BRCA2, BRIP1, CDH1, CTNNB1
18MP:00036315.8AKT1, BRCA1, BRCA2, BRIP1, CTNNB1, ERBB2

Drugs & Therapeutics for Ovarian Cancer, Somatic

About this section

Drugs for Ovarian Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
OlaparibapprovedPhase 4, Phase 3, Phase 2, Phase 1140763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
2Poly(ADP-ribose) Polymerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1340
3
Estradiolapproved, investigational, vet_approvedPhase 2131850-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
 
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
4
Fulvestrantapproved, investigationalPhase 2202129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
5
Paclitaxelapproved, vet_approvedPhase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
6
Rucaparibapproved, investigationalPhase 1, Phase 216283173-50-29931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
7
VeliparibinvestigationalPhase 299912444-00-911960529
Synonyms:
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
 
ABT 888
ABT-888
veliparib
8Hormone AntagonistsPhase 213180
9HormonesPhase 214415
10Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 213168
11MitogensPhase 21617
12Polyestradiol phosphatePhase 21318
13Estrogen Receptor AntagonistsPhase 2194
14Antineoplastic Agents, HormonalPhase 25592
15Antimitotic AgentsPhase 25657
16Albumin-Bound PaclitaxelPhase 22864
17EstrogensPhase 22542
18Antineoplastic Agents, PhytogenicPhase 25602
19Estrogen AntagonistsPhase 21349
20Estradiol 17 beta-cypionatePhase 21318
21Estradiol valeratePhase 21318979-32-8
22Estradiol 3-benzoatePhase 21318
23TalazoparibPhase 230
24Kavanutraceutical1619000-38-8

Interventional clinical trials:

(show all 19)
idNameStatusNCT IDPhase
1To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerRecruitingNCT02476968Phase 4
2Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
3Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusRecruitingNCT02983799Phase 2
4An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene AmplificationRecruitingNCT01953926Phase 2
5A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)Active, not recruitingNCT01482715Phase 1, Phase 2
6Phase II Study of BMN 673Active, not recruitingNCT02286687Phase 2
7Response to PARP Inhibitor Predicted by the RAD51 AssayNot yet recruitingNCT03044795Phase 2
8Selumetinib and Olaparib in Solid TumorsNot yet recruitingNCT03162627Phase 1
9BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian CancerCompletedNCT02963688
10Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.CompletedNCT02323568
11FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic StudyRecruitingNCT02984423
12Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and SpecificityRecruitingNCT02518256
13Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary PresentationRecruitingNCT02664389
14Clinical Significance of Germline BRCA MutationsRecruitingNCT00579488
15EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted TherapiesRecruitingNCT02701907
16A Study of Long-Term Responders on OlaparibRecruitingNCT02489058
17Prevalence of BRCA in Patients With Ovarian CancerActive, not recruitingNCT02222883
18Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf RegionNot yet recruitingNCT03082976
19Inherited Susceptible Genes Among Epithelial Ovarian CancerNot yet recruitingNCT03015376

Search NIH Clinical Center for Ovarian Cancer, Somatic

Genetic Tests for Ovarian Cancer, Somatic

About this section

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Ovarian Cancer, Somatic24 AKT1, ERBB2, PIK3CA

Anatomical Context for Ovarian Cancer, Somatic

About this section

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

36
Ovary, Breast

Publications for Ovarian Cancer, Somatic

About this section

Variations for Ovarian Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

70
id Symbol AA change Variation ID SNP ID
1BRCA1p.Cys61GlyVAR_007757rs28897672
2BRCA1p.Cys1697ArgVAR_020702rs80356993
3BRCA1p.Arg1699TrpVAR_075666rs55770810
4CTNNB1p.Ser37CysVAR_017625rs121913403
5CTNNB1p.Thr41IleVAR_017630rs121913413
6OPCMLp.Pro95ArgVAR_055421rs137852691
7PIK3CAp.His1047ArgVAR_026192rs121913279

Clinvar genetic disease variations for Ovarian Cancer, Somatic:

5 (show all 46)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_ 004985.4(KRAS): c.35G> A (p.Gly12Asp)SNVPathogenic/ Likely pathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
2KRASNM_ 033360.3(KRAS): c.34G> A (p.Gly12Ser)SNVPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
3PALB2NM_ 024675.3(PALB2): c.1050_ 1053delAACA (p.Thr351Argfs)deletionPathogenicrs515726060GRCh38Chr 16, 23635493: 23635496
4BRIP1NM_ 032043.2(BRIP1): c.2038_ 2039dupTT (p.Leu680Phefs)duplicationPathogenic/ Likely pathogenicrs587778134GRCh37Chr 17, 59853820: 59853821
5PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
6PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
7ERBB2NM_ 001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)SNVPathogenic/ Likely pathogenicrs28933370GRCh37Chr 17, 37881378: 37881378
8AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
9BRIP1NM_ 032043.2(BRIP1): c.1240C> T (p.Gln414Ter)SNVPathogenic/ Likely pathogenicrs368796923GRCh37Chr 17, 59876561: 59876561
10BRIP1NM_ 032043.2(BRIP1): c.1853_ 1854insG (p.Pro619Thrfs)insertionPathogenic/ Likely pathogenicrs587781985GRCh37Chr 17, 59857703: 59857704
11BRIP1NM_ 032043.2(BRIP1): c.2765T> G (p.Leu922Ter)SNVPathogenicrs587782410GRCh38Chr 17, 61685976: 61685976
12NC_ 012920.1: m.14743A> GSNVLikely pathogenicrs527236161GRCh37Chr MT, 14743: 14743
13MT-CYBNC_ 012920.1: m.14753C> TSNVLikely pathogenicrs527236162GRCh38Chr MT, 14753: 14753
14MT-CYBNC_ 012920.1: m.14784T> CSNVLikely pathogenicrs527236163GRCh37Chr MT, 14784: 14784
15MT-CYBNC_ 012920.1: m.15058C> TSNVLikely pathogenicrs527236171GRCh37Chr MT, 15058: 15058
16MT-CYBNC_ 012920.1: m.15098A> GSNVLikely pathogenicrs527236172GRCh37Chr MT, 15098: 15098
17MT-CYBNC_ 012920.1: m.15314G> ASNVLikely pathogenicrs527236176GRCh37Chr MT, 15314: 15314
18MT-CYBNC_ 012920.1: m.15328A> GSNVLikely pathogenicrs527236178GRCh37Chr MT, 15328: 15328
19MT-CYBNC_ 012920.1: m.15334C> TSNVLikely pathogenicrs527236179GRCh37Chr MT, 15334: 15334
20MT-CYBNC_ 012920.1: m.15363A> GSNVLikely pathogenicrs527236182GRCh37Chr MT, 15363: 15363
21MT-CYBNC_ 012920.1: m.15453T> CSNVLikely pathogenicrs527236184GRCh37Chr MT, 15453: 15453
22MT-CYBNC_ 012920.1: m.15459C> TSNVLikely pathogenicrs527236186GRCh37Chr MT, 15459: 15459
23MT-CYBNC_ 012920.1: m.15884G> ASNVLikely pathogenicrs527236195GRCh37Chr MT, 15884: 15884
24MT-TTNC_ 012920.1: m.15890C> ASNVLikely pathogenicrs527236196GRCh37Chr MT, 15890: 15890
25MT-TTNC_ 012920.1: m.15928G> ASNVLikely pathogenicrs527236198GRCh37Chr MT, 15928: 15928
26MT-TTNC_ 012920.1: m.15932T> GSNVLikely pathogenicrs527236199GRCh37Chr MT, 15932: 15932
27MT-TTNC_ 012920.1: m.15943T> CSNVLikely pathogenicrs527236200GRCh37Chr MT, 15943: 15943
28MT-CYBNC_ 012920.1: m.15061A> GSNVLikely pathogenicrs527236205GRCh37Chr MT, 15061: 15061
29MT-CYBNC_ 012920.1: m.15148G> ASNVLikely pathogenicrs527236206GRCh37Chr MT, 15148: 15148
30MT-CYBNC_ 012920.1: m.15259C> TSNVLikely pathogenicrs527236207GRCh37Chr MT, 15259: 15259
31MT-CYBNC_ 012920.1: m.15431G> ASNVLikely pathogenicrs193302993GRCh37Chr MT, 15431: 15431
32MT-CYBNC_ 012920.1: m.15452C> ASNVLikely pathogenicrs193302994GRCh37Chr MT, 15452: 15452
33MT-CYBNC_ 012920.1: m.15607A> GSNVLikely pathogenicrs193302996GRCh37Chr MT, 15607: 15607
34MT-CYBNC_ 012920.1: m.15670T> CSNVLikely pathogenicrs193302997GRCh37Chr MT, 15670: 15670
35PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
36CTNNB1NM_ 001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
37BRIP1NM_ 032043.2(BRIP1): c.290_ 293delACAA (p.Asn97Metfs)deletionPathogenic/ Likely pathogenicrs763009188GRCh37Chr 17, 59934505: 59934508
38BRIP1NM_ 032043.2(BRIP1): c.2990_ 2993delCAAA (p.Thr997Argfs)deletionPathogenic/ Likely pathogenicrs771028677GRCh37Chr 17, 59761414: 59761417
39PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
40PIK3CANM_ 006218.3(PIK3CA): c.1258T> C (p.Cys420Arg)SNVPathogenic/ Likely pathogenicrs121913272GRCh37Chr 3, 178927980: 178927980
41BRIP1NM_ 032043.2(BRIP1): c.2111T> A (p.Leu704Ter)SNVLikely pathogenicrs1057517643GRCh38Chr 17, 61744578: 61744578
42BRIP1NM_ 032043.2(BRIP1): c.205+1delGdeletionLikely pathogenicrs1057517648GRCh38Chr 17, 61859795: 61859795
43PIK3CANM_ 006218.3(PIK3CA): c.1637A> G (p.Gln546Arg)SNVPathogenic/ Likely pathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
44PRKNPARK2, DELdeletionPathogenic
45OPCMLNM_ 001012393.2(OPCML): c.263C> G (p.Pro88Arg)SNVPathogenicrs137852691GRCh37Chr 11, 132527098: 132527098
46RRAS2NM_ 001177314.1(RRAS2): c.110A> T (p.Gln37Leu)SNVPathogenicrs113954997GRCh38Chr 11, 14294844: 14294844

Cosmic variations for Ovarian Cancer, Somatic:

8 (show all 20)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM28511EGFRovary,NS,carcinoma,adenocarcinomac.2108T>Cp.L703P5
2COSM12373EGFRovary,NS,carcinoma,adenocarcinomac.2159C>Tp.S720F5
3COSM53235EGFRovary,NS,carcinoma,adenocarcinomac.2481C>Tp.Y827Y5
4COSM760PIK3CAovary,NS,carcinoma,adenocarcinomac.1624G>Ap.E542K5
5COSM53224EGFRovary,NS,carcinoma,adenocarcinomac.2173A>Gp.T725A5
6COSM22992EGFRovary,NS,carcinoma,adenocarcinomac.2161G>Ap.G721S5
7COSM28286EGFRovary,NS,carcinoma,adenocarcinomac.2494C>Tp.R832C5
8COSM53225EGFRovary,NS,carcinoma,adenocarcinomac.2112G>Ap.L704L5
9COSM6224EGFRovary,NS,carcinoma,adenocarcinomac.2573T>Gp.L858R5
10COSM53228EGFRovary,NS,carcinoma,adenocarcinomac.2123A>Gp.K708R5
11COSM53232EGFRovary,NS,carcinoma,adenocarcinomac.2122A>Gp.K708E5
12COSM53266EGFRovary,NS,carcinoma,adenocarcinomac.2165C>Tp.A722V5
13COSM53229EGFRovary,NS,carcinoma,adenocarcinomac.2232C>Ap.I744I5
14COSM53213EGFRovary,NS,carcinoma,adenocarcinomac.2604A>Tp.E868D5
15COSM53231EGFRovary,NS,carcinoma,adenocarcinomac.2559C>Tp.I853I5
16COSM53230EGFRovary,NS,carcinoma,adenocarcinomac.2597A>Gp.E866G5
17COSM53265EGFRovary,NS,carcinoma,adenocarcinomac.2556G>Tp.K852N5
18COSM53226EGFRovary,NS,carcinoma,adenocarcinomac.2099A>Gp.N700S5
19COSM53264EGFRovary,NS,carcinoma,adenocarcinomac.2174C>Tp.T725M5
20COSM53227EGFRovary,NS,carcinoma,adenocarcinomac.2506C>Ap.R836S5

Expression for genes affiliated with Ovarian Cancer, Somatic

About this section
Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for genes affiliated with Ovarian Cancer, Somatic

About this section

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 84)
idSuper pathwaysScoreTop Affiliating Genes
19.9AKT1, PIK3CA
29.8CDH1, CTNNB1
39.8AKT1, CDH1
4
Show member pathways
9.6AKT1, CTNNB1, PIK3CA
5
Show member pathways
9.6AKT1, CTNNB1, PIK3CA
69.6AKT1, CTNNB1, PIK3CA
79.5AKT1, ERBB2, PIK3CA
8
Show member pathways
9.5AKT1, ERBB2, PIK3CA
99.5CDH1, CTNNB1, PIK3CA
109.5CDH1, CTNNB1, PIK3CA
119.5AKT1, CDH1, PIK3CA
129.5AKT1, CDH1, PIK3CA
139.5AKT1, CTNNB1, ERBB2
14
Show member pathways
9.5AKT1, KRAS, PIK3CA
159.5AKT1, KRAS, PIK3CA
16
Show member pathways
9.5AKT1, KRAS, PIK3CA
17
Show member pathways
9.5AKT1, KRAS, PIK3CA
189.5AKT1, KRAS, PIK3CA
199.5AKT1, KRAS, PIK3CA
20
Show member pathways
9.5AKT1, KRAS, PIK3CA
219.5AKT1, KRAS, PIK3CA
229.5AKT1, KRAS, PIK3CA
23
Show member pathways
9.5AKT1, KRAS, PRKN
249.5CDH1, CTNNB1, ERBB2
25
Show member pathways
9.5ERBB2, KRAS, PIK3CA
26
Show member pathways
9.4AKT1, ERBB2, KRAS
279.4CDH1, CTNNB1, KRAS
28
Show member pathways
9.3CDH1, ERBB2, KRAS
299.3KRAS, PRKN, RRAS2
30
Show member pathways
9.2AKT1, CTNNB1, ERBB2, PIK3CA
31
Show member pathways
9.2AKT1, KRAS, RRAS2
32
Show member pathways
9.2AKT1, KRAS, RRAS2
339.2AKT1, CDH1, CTNNB1, PIK3CA
349.2ERBB2, KRAS, RRAS2
359.2AKT1, CTNNB1, KRAS, PIK3CA
369.2AKT1, CTNNB1, KRAS, PIK3CA
379.2AKT1, CDH1, ERBB2, PIK3CA
38
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
39
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
409.1AKT1, ERBB2, KRAS, PIK3CA
41
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
42
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
43
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
449.1AKT1, CTNNB1, ERBB2, KRAS
459.1AKT1, CDH1, CTNNB1, KRAS
469.0AKT1, BRCA1, CTNNB1
479.0AKT1, BRCA1, CTNNB1
48
Show member pathways
9.0AKT1, KRAS, PIK3CA, RRAS2
49
Show member pathways
9.0AKT1, KRAS, PIK3CA, RRAS2
509.0AKT1, KRAS, PIK3CA, RRAS2

GO Terms for genes affiliated with Ovarian Cancer, Somatic

About this section

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.5CDH1, CTNNB1
2catenin complexGO:001634210.5CDH1, CTNNB1
3flotillin complexGO:001660010.5CDH1, CTNNB1
4lateral elementGO:00008009.8BRCA1, BRCA2
5protein complexGO:00432348.2AKT1, BRCA1, BRCA2, CTNNB1, PRKN

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 34)
idNameGO IDScoreTop Affiliating Genes
1anoikisGO:004327610.7AKT1, PIK3CA
2negative regulation of macroautophagyGO:001624210.6AKT1, PIK3CA
3negative regulation of release of cytochrome c from mitochondriaGO:009020110.6AKT1, PRKN
4entry of bacterium into host cellGO:003563510.5CDH1, CTNNB1
5epithelial tube branching involved in lung morphogenesisGO:006044110.5CTNNB1, KRAS
6regulation of myelinationGO:003164110.5AKT1, CTNNB1
7positive regulation of nitric-oxide synthase activityGO:005100010.4AKT1, KRAS
8cellular processGO:000998710.4CTNNB1, RRAS2
9negative regulation of neuron deathGO:190121510.3AKT1, CTNNB1, PRKN
10cellular response to growth factor stimulusGO:007136310.3AKT1, CTNNB1, ERBB2
11phosphatidylinositol-mediated signalingGO:004801510.3AKT1, ERBB2, PIK3CA
12negative regulation of neuron apoptotic processGO:004352410.2KRAS, PIK3CA, PRKN
13inner cell mass cell proliferationGO:000183310.2BRCA2, PALB2
14ERBB2 signaling pathwayGO:003812810.2ERBB2, KRAS, PIK3CA
15regulation of phosphatidylinositol 3-kinase signalingGO:001406610.1AKT1, ERBB2, PIK3CA
16striated muscle cell differentiationGO:005114610.1AKT1, KRAS
17positive regulation of histone H3-K4 methylationGO:005157110.0BRCA1, CTNNB1
18protein K6-linked ubiquitinationGO:008502010.0BRCA1, PRKN
19vasculature developmentGO:00019449.9CTNNB1, PIK3CA
20chordate embryonic developmentGO:00430099.9BRCA1, BRCA2
21DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:00069789.9BRCA1, BRCA2
22cell proliferationGO:00082839.8AKT1, BRCA2, CTNNB1, ERBB2
23cellular response to indole-3-methanolGO:00716819.7BRCA1, CDH1, CTNNB1
24negative regulation of gene expressionGO:00106299.7AKT1, BRIP1, CTNNB1, PRKN
25DNA recombinationGO:00063109.4BRCA1, BRCA2, PALB2
26double-strand break repair via homologous recombinationGO:00007249.4BRCA1, BRCA2, PALB2
27double-strand break repairGO:00063029.2BRCA1, BRCA2, BRIP1
28regulation of signal transduction by p53 class mediatorGO:19017969.2AKT1, BRCA1, BRIP1
29positive regulation of gene expressionGO:00106289.0BRCA1, CTNNB1, ERBB2, KRAS, PRKN
30DNA repairGO:00062818.8BRCA1, BRCA2, BRIP1, PALB2
31DNA synthesis involved in DNA repairGO:00007318.8BRCA1, BRCA2, BRIP1, PALB2
32positive regulation of transcription, DNA-templatedGO:00458938.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1
33cellular response to DNA damage stimulusGO:00069748.5AKT1, BRCA1, BRCA2, BRIP1, PALB2
34strand displacementGO:00007328.5BRCA1, BRCA2, BRIP1, PALB2

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GTPase activating protein bindingGO:003279410.4AKT1, CDH1
2enzyme bindingGO:00198999.4AKT1, BRCA1, CTNNB1, PRKN
3nucleotide bindingGO:00001668.8AKT1, BRIP1, ERBB2, KRAS

Sources for Ovarian Cancer, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet